Champions Oncology Inc

Champions Oncology Inc, based in Gaithersburg, MD, is a leading provider of oncology Contract Research Organization (CRO) services, specializing in preclinical and clinical specialty testing to advance drug development globally. With over 1,400 patient-derived xenograft (PDX) models and a proprietary oncology data platform, the company offers innovative solutions that enhance the efficiency and effectiveness of cancer research and treatment. Committed to driving breakthrough advancements in oncology, Champions Oncology partners with pharmaceutical and biotech companies to provide clinically relevant preclinical models and analytical services, including flow cytometry and next-generation sequencing. The company's focus on scientific excellence and customized testing solutions aims to improve patient outcomes and accelerate the path from discovery to clinical success. Generated from the website

CEL-SCI Corporation, based in Elkridge, MD, is a biotechnology company dedicated to advancing cancer treatment through innovative immunotherapy solutions. Their flagship product, Multikine, aims to enhance patients' immune responses before the onset of traditional cancer therapies, such as surgery, radiation, and chemotherapy. The company has made significant strides in clinical research, highlighted by the largest Phase III trial in head and neck cancer involving 928 patients. CEL-SCI's mission is to improve treatment outcomes by leveraging the body's natural defense mechanisms, with a vision to fundamentally change cancer therapy. Generated from the website

Incorporated in 1989, Otsuka America Pharmaceutical is a health care company that commercializes its products throughout North America. It offers products under the ABILIFY Tablets1 and PLETAL Tablets2 brands. The company works in collaboration with Bristol-Myers Squibb, which co-develops and co-promotes ABILIFY. Otsuka America Pharmaceutical has also merged with Meretek Diagnostics to form the Meretek Diagnostics Group under the Medical Device Division of OAPI. It focuses on neuroscience, cardiovascular, oncologic and gastrointestinal therapeutic treatments. The company operates Otsuka Maryland Research Institute, which was established as a wholly-owned subsidiary of OAPI to research and develop a variety of health care products. Otsuka America Pharmaceutical is a part of Otsuka Pharmaceutical Group.